PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 200 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,938,098 | -29.6% | 226,144 | -8.1% | 0.00% | -33.3% |
Q2 2023 | $9,861,307 | -6.7% | 246,102 | -5.0% | 0.00% | 0.0% |
Q1 2023 | $10,568,402 | +6.5% | 258,966 | +0.8% | 0.00% | 0.0% |
Q4 2022 | $9,923,000 | -39.7% | 257,009 | -16.9% | 0.00% | -50.0% |
Q3 2022 | $16,449,000 | -9.4% | 309,236 | -0.7% | 0.01% | 0.0% |
Q2 2022 | $18,162,000 | -7.4% | 311,544 | +21.2% | 0.01% | 0.0% |
Q1 2022 | $19,621,000 | +27.1% | 257,087 | +0.2% | 0.01% | +50.0% |
Q4 2021 | $15,443,000 | -7.4% | 256,655 | -13.9% | 0.00% | -20.0% |
Q3 2021 | $16,684,000 | -19.0% | 297,934 | -12.2% | 0.01% | -16.7% |
Q2 2021 | $20,594,000 | -14.6% | 339,359 | -1.4% | 0.01% | -25.0% |
Q1 2021 | $24,125,000 | +49.6% | 344,208 | +27.7% | 0.01% | +33.3% |
Q4 2020 | $16,129,000 | +12.0% | 269,534 | +12.5% | 0.01% | 0.0% |
Q3 2020 | $14,407,000 | +17.2% | 239,635 | +2.3% | 0.01% | +20.0% |
Q2 2020 | $12,290,000 | +70.2% | 234,246 | +8.8% | 0.01% | +25.0% |
Q1 2020 | $7,220,000 | -26.7% | 215,339 | -1.0% | 0.00% | 0.0% |
Q4 2019 | $9,850,000 | +16.9% | 217,439 | -1.7% | 0.00% | 0.0% |
Q3 2019 | $8,423,000 | +140.5% | 221,234 | +140.4% | 0.00% | +100.0% |
Q1 2019 | $3,503,000 | -12.3% | 92,040 | -0.9% | 0.00% | 0.0% |
Q4 2018 | $3,995,000 | +66.9% | 92,857 | +90.8% | 0.00% | +100.0% |
Q3 2018 | $2,393,000 | +47.5% | 48,676 | -3.8% | 0.00% | 0.0% |
Q2 2018 | $1,622,000 | -69.2% | 50,605 | -70.0% | 0.00% | -50.0% |
Q1 2018 | $5,259,000 | -60.2% | 168,868 | -41.7% | 0.00% | -66.7% |
Q4 2017 | $13,219,000 | +21.3% | 289,584 | -0.2% | 0.01% | +20.0% |
Q3 2017 | $10,900,000 | -28.7% | 290,278 | -9.3% | 0.01% | -37.5% |
Q2 2017 | $15,286,000 | +18.6% | 320,019 | +13.3% | 0.01% | +14.3% |
Q1 2017 | $12,884,000 | +1154.5% | 282,531 | +788.0% | 0.01% | +600.0% |
Q4 2016 | $1,027,000 | -80.4% | 31,817 | -79.2% | 0.00% | -66.7% |
Q3 2016 | $5,239,000 | -35.0% | 153,122 | -35.9% | 0.00% | -40.0% |
Q2 2016 | $8,054,000 | -23.4% | 238,746 | +20.2% | 0.01% | -16.7% |
Q1 2016 | $10,519,000 | +91.7% | 198,563 | +178.1% | 0.01% | +100.0% |
Q4 2015 | $5,487,000 | -86.7% | 71,389 | -92.9% | 0.00% | -88.5% |
Q3 2015 | $41,339,000 | -33.0% | 1,006,127 | +15.3% | 0.03% | -25.7% |
Q2 2015 | $61,710,000 | -25.4% | 872,598 | -6.3% | 0.04% | -27.1% |
Q1 2015 | $82,767,000 | +11.1% | 931,536 | +10.8% | 0.05% | +11.6% |
Q4 2014 | $74,521,000 | +5.0% | 840,523 | +14.8% | 0.04% | 0.0% |
Q3 2014 | $70,963,000 | +48.4% | 732,197 | +40.7% | 0.04% | +53.6% |
Q2 2014 | $47,817,000 | +95.7% | 520,545 | +49.1% | 0.03% | +86.7% |
Q1 2014 | $24,439,000 | +34.4% | 349,180 | +10.4% | 0.02% | +36.4% |
Q4 2013 | $18,182,000 | +62.5% | 316,240 | +35.9% | 0.01% | +57.1% |
Q3 2013 | $11,191,000 | +938.1% | 232,700 | +526.0% | 0.01% | +600.0% |
Q2 2013 | $1,078,000 | – | 37,173 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |